Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcherCritical unmet need: 1 in 31 ...

Day One Biopharmaceuticals (DAWN) has recently drawn investor attention after a stretch of mixed share performance, with gains over the past month and past 3 months contrasting with a weaker one year ...

CEO Jeremy Bender highlighted the strong performance of OJEMDA, with Q1 2025 net product revenue reaching $30.5 million, driven by a 16% increase in quarterly scripts compared to the prior quarter. He ...

Management projected full-year 2025 net product revenues of $140 million to $150 million for OJEMDA, citing "strong and persistent demand, deepening prescriber adoption, and consistent payer coverage" ...

Day One Biopharmaceuticals, Inc. (DAWN) shares rallied 26.7% in the last trading session to close at $11.33. This move can be attributable to notable volume with a higher number of shares being traded ...

Day One Biopharmaceuticals’ fair value estimate remains steady at $22.25 per share, even as the Mersana acquisition adds a second antibody drug conjugate and broadens its oncology platform. While the ...

Shares of Day One Biopharmaceuticals, Inc. (DAWN) have gained 22.5% over the past four weeks to close the last trading session at $10.73, but there could still be a solid upside left in the stock if ...

NIJMEGEN, The Netherlands--(BUSINESS WIRE)--Synthon Biopharmaceuticals B.V., a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless ...

XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced that it is working diligently to close the acquisition ...

The tremendous potential of the emerging class of medicines known as biotherapeutics — medicines produced from living cells — is exciting new terrain for researchers, industry and health care ...